Straumann Set to Bolster Villeret Site and Localize Production for China in Shanghai

Straumann Holding AG plans to invest CHF 60 to 80 million in its Villeret site over the next five years. This move aims to enhance advanced technologies and modernize infrastructure. The focus remains on high value-added products, such as the iEXCEL implant system. Despite workforce adjustments affecting up to 250 positions, strategic enhancements aim to sustain long-term growth.

Simultaneously, Straumann will transfer production for China to a newly licensed site in Shanghai. This strategic shift supports participation in China's VBP system, crucial for market access and growth. Villeret has more than doubled its workforce in seven years, fueled by global demand and China’s VBP system introduction in 2023.